Akero Looks Ahead To Phase III In Cirrhotic NASH Despite Phase IIb Miss On Fibrosis

 
• By Joseph Haas

Already prepping Phase III trials of efruxifermin in pre-cirrhotic NASH patients, Akero says it will go ahead with Phase III plans in cirrhotic patients despite missing the fibrosis endpoint in a Phase IIb trial.

Mixed data
Investors and analysts differed on the meaning of Akero's latest NASH data • Source: Shutterstock

More from Clinical Trials

More from R&D